OptiNose Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
132
- Stock Symbol
-
OPTN
- Share Price
-
$0.92
- (As of Wednesday Closing)
OptiNose General Information
Description
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Contact Information
Website
www.optinose.comCorporate Office
- 1020 Stony Hill Road
- Suite 300
- Yardley, PA 19067
- United States
Corporate Office
- 1020 Stony Hill Road
- Suite 300
- Yardley, PA 19067
- United States
OptiNose Timeline
OptiNose Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.92 | $0.93 | $0.80 - $2.10 | $139M | 151M | 728K | -$0.34 |
OptiNose Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 197,294 | 208,981 | 275,329 | 177,588 |
| Revenue | 75,058 | 70,987 | 76,276 | 74,652 |
| EBITDA | (22,787) | (18,080) | (57,971) | (65,729) |
| Net Income | (40,910) | (35,483) | (74,833) | (82,296) |
| Total Assets | 131,872 | 107,729 | 144,222 | 166,071 |
| Total Debt | 126,158 | 131,749 | 131,171 | 130,702 |
OptiNose Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OptiNose Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
OptiNose Comparisons
Industry
Financing
Details
000 00
OptiNose Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| LTS Lohmann Therapie-Systeme | Private Equity-Backed | Andernach, Germany | 0000 | 0000000000 |
OptiNose Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OptiNose Patents
OptiNose Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230285278-A1 | Methods for treating chronic rhinosinusitis | Pending | 06-Mar-2022 | 0000000000 | |
| US-20220296825-A1 | Exhalation delivery system for and method of treating sinus disease | Pending | 04-Oct-2018 | 000000000 | 0 |
| US-20170147664-A1 | In-memory key-value store for a multi-model database | Active | 19-Nov-2015 | 0000000000 | |
| US-10360233-B2 | In-memory key-value store for a multi-model database | Active | 19-Nov-2015 | 0000000000 | 00 |
| JP-6937690-B2 | Intranasal administration | Active | 19-Nov-2014 | A61M15/08 |
OptiNose Executive Team (24)
| Name | Title | Board Seat |
|---|---|---|
| Ramy Mahmoud MD | Chief Executive Officer & Board Member | |
| Anthony Krick | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Karen Brophy | Chief Human Resources Officer | |
| Michael Marino | Secretary, Administration & Chief Legal Officer, Legal | |
| Paul Spence | Executive |
OptiNose Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Catherine Owen | Self | Board Member | 000 0000 |
| Per Djupesland Ph.D | Self | Board Member, Co-Founder & Chief Scientific Officer | 000 0000 |
| R. Fletcher | Self | Chairman & Board Member | 000 0000 |
| Ramy Mahmoud MD | OptiNose | Chief Executive Officer & Board Member | 000 0000 |
| Sandra Helton | Self | Board Member | 000 0000 |
OptiNose Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
OptiNose Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OptiNose ESG
Risk Overview
Risk Rating
Updated December, 11, 2023
35.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
OptiNose FAQs
-
When was OptiNose founded?
OptiNose was founded in 2000.
-
Who is the founder of OptiNose?
Trond Holand is the founder of OptiNose.
-
Who is the CEO of OptiNose?
Ramy Mahmoud MD is the CEO of OptiNose.
-
Where is OptiNose headquartered?
OptiNose is headquartered in Yardley, PA.
-
What is the size of OptiNose?
OptiNose has 132 total employees.
-
What industry is OptiNose in?
OptiNose’s primary industry is Drug Delivery.
-
Is OptiNose a private or public company?
OptiNose is a Public company.
-
What is OptiNose’s stock symbol?
The ticker symbol for OptiNose is OPTN.
-
What is the current stock price of OptiNose?
As of 11-Sep-2024 the stock price of OptiNose is $0.92.
-
What is the current market cap of OptiNose?
The current market capitalization of OptiNose is $139M.
-
What is OptiNose’s current revenue?
The trailing twelve month revenue for OptiNose is $75.1M.
-
Who are OptiNose’s competitors?
LTS Lohmann Therapie-Systeme is a competitor of OptiNose.
-
What is OptiNose’s annual earnings per share (EPS)?
OptiNose’s EPS for 12 months was -$0.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
